Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07589608

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will last about 64 weeks.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Overweight Body Weight Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler, Arizona, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • See Master Protocol CWMM (NCT06143956) for inclusion criteria

Exclusion criteria

In addition to exclusion criteria in Master Protocol CWMM (NCT06143956):

  • Have type 1 diabetes or type 2 diabetes
  • Have an ongoing history of bradyarrhythmia and/or sinus bradycardia
  • Have an elevated resting pulse rate (greater than 100 bpm) or reduced resting pulse rate (less than 60 bpm)
  • Have a history of acute or chronic pancreatitis
  • All concomitant medications should be at a stable dose for at least 3 months prior to screening

Treatment and study plan

Macupatide

Drug

Administered SC

Other names: LY3532226

Eloralintide

Drug

Administered SC

Other names: LY3841136

Placebo

Drug

Administered SC

Primary outcomes

  1. Percent Change from Baseline in Body Weight

    Time frame: Baseline, Week 36

Secondary outcomes

  1. Percent Change from Baseline in Body Weight

    Time frame: Baseline, Week 48

  2. Change from Baseline in Body Weight

    Time frame: Baseline, Week 36

  3. Percentage of Participants who Achieve ≥5% Body Weight Reduction

    Time frame: Week 36

  4. Percentage of Participants who Achieve ≥10% Body Weight Reduction

    Time frame: Week 36

  5. Change from Baseline in Body Mass Index (BMI)

    Time frame: Baseline, Week 36

Study contacts

Contact information is provided by the study sponsor or research team.

Physicians interested in becoming principal investigators please contact

CONTACT

[email protected]

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

CONTACT

[email protected]

317-615-4559

Sponsors and collaborators

Lead sponsor

Eli Lilly and Company

Industry

Registry information

Official study title

A Phase 2b, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and Without Type 2 Diabetes

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
May 15, 2026
Registry last updated
Aug 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.